reptides › weight loss › semaglutide

semaglutide

ozempic. wegovy. rybelsus. the GLP-1 drug that made obesity a pharmacology problem.

tier S · weight loss · 14.9% STEP 1 wt loss

verdict

the GLP-1 that broke containment. ozempic, wegovy, rybelsus. same molecule, three labels.

if you're asking about Ozempic vs Wegovy — same drug, different doses, different FDA labels, different insurance pathways. Ozempic tops out at 2 mg for T2D. Wegovy goes to 2.4 mg for obesity. Rybelsus is the oral 14 mg formulation for T2D only. the choice is downstream of what your insurance covers, not which molecule is stronger.

if you're asking what happens when you stop — STEP-4 extension showed two-thirds of the weight loss returns within 12 months off the drug. this is chronic medication by design, not a course of treatment. metabolic adaptation is the mechanism and the catch.

if you came in via the compounded route — the April 2026 503B proposal would close most compounded pathways for sema. compounded versions vary by source; some are chemically identical, some aren't, and COAs are uneven. roughly 2 million Americans used compounded semaglutide during the 2023-2024 shortage window. the regulatory direction is one-way from here.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why S-tier

works. period. drug-tier evidence from multiple phase III trials. 15% body weight loss at 2.4mg weekly, sustained while on drug, rebounds if stopped. cardiovascular protection documented independently. side effect profile is rough for many (GI) but manageable. S because the bar for S is drug-tier human evidence and sema clears it easily.

the core tension

The weight-loss numbers are real. The cardiovascular numbers are real. The mechanism is ongoing: GLP-1 agonism works as long as you're on it, and discontinuation returns appetite to baseline. Whether that's a bug or a feature depends on whether you think obesity is an acute problem or a chronic one.

what it is

Semaglutide is a 31-amino-acid GLP-1 receptor agonist. A modified analog of the natural gut hormone GLP-1 with two engineering tricks: an aminoisobutyric acid at position 2 (DPP-4 protection) and a C-18 fatty acid that reversibly binds albumin (one-week half-life). Sold by Novo Nordisk as Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral T2D). A higher-dose oral semaglutide for obesity (25 mg / 50 mg, OASIS-1 phase 3) sits under FDA review.

what it does

Slows gastric emptying, suppresses glucagon, glucose-dependent insulin release, and acts on hypothalamic satiety centers to quiet 'food noise.' STEP-1 produced 14.9% mean weight loss at 68 weeks. SELECT (n=17,604) showed a 20% relative risk reduction in major cardiovascular events in non-diabetic adults. The drug stopped being just a weight-loss molecule in 2023.

origin

Developed at Novo Nordisk by chemist Lotte Bjerre Knudsen, the same scientist who built liraglutide. FDA approved Ozempic in 2017 for type 2 diabetes, Rybelsus in 2019 (oral T2D), and Wegovy in 2021 for chronic weight management. The high-dose oral semaglutide for obesity (OASIS-class) is under FDA review. Novo's market cap peaked at $604 billion in March 2024, briefly the largest company in Europe.

why researchers are interested

It works at scale. Roughly 10 million Americans on a GLP-1 by 2025, 12% of US adults currently taking. Pop-culture penetration was inevitable once Elon Musk and Oprah were public users and TikTok ran with it. The 'food noise quieting' phenomenon is a real subjective effect that earlier diet drugs never produced. Adjacent industries (restaurants, snack food) started disclosing GLP-1 impact in earnings calls.

does it work

Yes. Multiple phase-3 trials, cardiovascular outcomes data, kidney-outcome data via FLOW. Wegovy 2.4mg got FDA accelerated approval for non-cirrhotic MASH with stage 2-3 fibrosis in August 2025 (ESSENCE phase 3, 63% MASH resolution vs 34% placebo) - first GLP-1 ever approved for MASH. The catch: STEP-4 showed two-thirds of lost weight returns within 12 months of discontinuation, and EVOKE/EVOKE+ (n=3,808, Lancet 2026) was the first major NEGATIVE phase 3 readout for semaglutide - oral 14mg failed to slow Alzheimer's progression. This is a long-term metabolic drug, not a CNS one, and tirzepatide now beats it head-to-head on weight loss (SURMOUNT-5: 20.2% vs 13.7%). The S-tier evidence claim still holds.

claims vs the data

  • causes significant weight loss — supported — 14.9% avg at 2.4mg weekly in step-1. phase III, n=1961.
  • reduces cardiovascular events — supported — SELECT trial 2023: 20% relative risk reduction in MACE, n=17,604 non-diabetics.
  • keeps weight off after stopping — contradicted — step-4 extension: two-thirds of lost weight returned within 1 year off-drug.
  • no serious side effects — contradicted — 74-87% report GI sides. gastroparesis lawsuits ongoing since 2023. pancreatitis and gallbladder events rare but real.
  • treats alcohol use disorder and addiction — weak — small trials promising, phase III not yet started, phase 2 RCT showed reduced craving and drinking in AUD.
  • safe long-term (10+ years) — unverified — longest clinical follow-up ~5 years. rodent thyroid C-cell signal. no human equivalent detected yet.
  • compounded versions are identical — partially true — some are chemically identical. some aren't. without COA you can't tell. 2 million americans used compounded 2023-2024.
  • the suicidal ideation warning still belongs on GLP-1 obesity labels — contradicted — FDA's 2026 review did not find increased suicidal ideation or behavior with GLP-1 receptor agonists. The agency requested removal of that warning from Wegovy, Saxenda, and Zepbound labels after trial meta-analysis and Sentinel claims review. That does not make mood symptoms irrelevant, but it changes the evidence grade of the warning.

key facts

  • molecular formula: C₁₈₇H₂₉₁N₄₅O₅₉
  • molecular weight: 4113.58 g/mol
  • amino acids: 31
  • half-life: ~1 week (acylated)
  • type: GLP-1 receptor agonist
  • CAS: 910463-68-2
  • 14.9% avg weight loss (step-1)
  • $33B 2025 global revenue
  • ~10M americans on GLP-1
  • $604B→$180B novo market cap peak→now

frequently asked questions

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist, FDA-approved as Ozempic (type 2 diabetes) and Wegovy (obesity). It is a modified version of the natural incretin hormone GLP-1, with a half-life extended to approximately one week via a fatty acid chain attached to the peptide backbone.

What does semaglutide do?

Semaglutide reduces appetite, delays gastric emptying, and enhances insulin response to meals. The STEP 1 obesity trial showed mean weight loss of approximately 15% of body weight over 68 weeks. For type 2 diabetes, it produces meaningful reductions in HbA1c and cardiovascular risk markers.

How is semaglutide typically administered?

Semaglutide is administered as a once-weekly subcutaneous injection. FDA-approved Wegovy dosing starts at 0.25mg per week and titrates over 16-20 weeks to the maintenance dose of 2.4mg per week. Ozempic dosing for diabetes is lower, typically maintaining at 0.5-2mg per week.

What are the side effects of semaglutide?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These typically improve over weeks of treatment. Less common serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors based on rodent studies. FDA reviewed and removed the suicidal-behavior-and-ideation warning from the GLP-1 class label in 2026 after concluding the post-2024 evaluation. EMA continues to monitor a separate non-arteritic anterior ischemic optic neuropathy (NAION) optic-nerve signal flagged through European pharmacovigilance, currently preliminary and not yet a labeled warning.

Is semaglutide FDA approved?

Yes, in three injectable and oral forms: Ozempic (2017, type 2 diabetes), Rybelsus (2019, oral type 2 diabetes), Wegovy injection (2021, chronic weight management), with the March 2026 Wegovy HD 7.2 mg high-dose label and a MASH indication for moderate-to-advanced fibrosis. A higher-dose oral semaglutide for obesity (OASIS-class, 25 mg / 50 mg) is under FDA review.

How much does semaglutide cost?

Branded Wegovy and Ozempic retail for approximately $900-1400 per month without insurance. Compounding pharmacies have offered semaglutide at $200-500 per month during FDA-designated shortage periods. On the research-chemical market it sells for a fraction of the branded-drug price.

related peptides

  • cagrisema — semaglutide + amylin combo, FDA review 2026
  • tirzepatide — stronger dual-agonist successor
  • liraglutide — the daily predecessor it replaced
  • retatrutide — next-gen triple agonist in trials

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.